Private equity firms Cobro Ventures and Perceptive Advisors led a $150m Series B funding round in C4 Therapeutics, a biotechnology company. Additional new equity investors in the round included Adage Capital Management, Axil Capital, Bain Capital Life Sciences, Commodore Capital, 3E Bioventures Capital, HBM Healthcare Investments, Lightchain Capital, Logos Capital, Mizuho Securities Principal Investment, Nextech, RA Capital Management, RTW Investments, Sphera Funds Management, Taiwania Capital Management, Yonjin Venture, and funds and accounts managed by T. Rowe Price Associates, and Janus Henderson Investors. Existing investors also participated. “C4 Therapeutics is a pioneer in this exciting and promising new protein degradation space. With their strong science and world class team we have no doubt that they will be able to bring powerful new therapeutics to patients and we are excited to collaborate with C4T on this important mission," Adam Stone, Perceptive Advisors Chief Investment Officer.